Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

被引：1

作者：

Highland, Kristin B. ^{[1
]}

Kuwana, Masataka ^{[2
]}

Azuma, Arata ^{[3
]}

Fischer, Aryeh ^{[4
]}

Maher, Toby M. ^{[5
,6
]}

Mayes, Maureen D. ^{[7
]}

Raghu, Ganesh ^{[8
]}

Girard, Mannaig ^{[9
]}

Kohlbrenner, Veronika ^{[10
]}

Clerisme-Beaty, Emmanuelle ^{[11
]}

Alves, Margarida ^{[11
]}

Distler, Oliver ^{[12
]}

机构：

[1] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA

[2] Nippon Med Sch, Dept Allergy & Rheumatol, Grad Sch Med, Tokyo, Japan

[3] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[4] Univ Colorado, Sch Med, Denver, CO USA

[5] Imperial Coll London, Natl Heart & Lung Inst, London, England

[6] Royal Brompton Hosp, Res Clin Res Facil, Natl Inst Hlth, London, England

[7] Univ Texas Houston, McGovern Med Sch, Div Rheumatol & Clin Immunogenet, Houston, TX USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Boehringer Ingelheim France SAS, Reims, France

[10] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[11] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[12] Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland

来源：

关键词：

D O I：

10.1183/13993003.congress-2019.PA4731

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA4731

引用

页数：2